Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
Source: View publication →
The PLCO trial was a landmark randomized controlled trial designed to determine whether specific screening modalities—PSA and DRE for prostate, chest X-ray for lung, flexible sigmoidoscopy for colorectal, and CA-125 with transvaginal ultrasound for ovarian cancer—reduce disease-specific mortality in an average-risk population.
Key Findings
Study Design
Study Limitations
Clinical Significance
The PLCO trial fundamentally shaped modern cancer screening guidelines. It demonstrated that annual chest X-rays, PSA testing, and CA-125 with transvaginal ultrasound do not significantly reduce disease-specific mortality in average-risk populations, shifting clinical practice away from these modalities for routine screening. Conversely, it validated lower endoscopy (flexible sigmoidoscopy) as a highly effective intervention for preventing colorectal cancer and reducing CRC mortality.
Historical Context
Initiated in 1992 by the National Cancer Institute, the PLCO trial was conceived during a period of rapidly increasing, yet unproven, cancer screening practices—most notably the widespread, unchecked adoption of PSA testing in the late 1980s. Enrolling nearly 155,000 participants over eight years, it remains one of the most ambitious cancer screening trials in history and established a vast biospecimen repository (EEMS) that continues to drive epidemiologic and multi-omic research today.
Guided Discussion
High-yield insights from every perspective
Why did the PLCO trial choose disease-specific mortality as its primary endpoint instead of survival time after diagnosis or overall mortality?
Key Response
Survival time after diagnosis is subject to lead-time bias (early detection simply increases time aware of the disease without extending life) and length-time bias (screening disproportionately detects slow-growing tumors). Disease-specific mortality avoids these biases and is more sensitive to the intervention than overall mortality, which is diluted by deaths from other causes.
Based on the findings of the PLCO trial, how should you counsel an average-risk 60-year-old asymptomatic woman who requests a CA-125 test and transvaginal ultrasound to screen for ovarian cancer?
Key Response
The PLCO trial demonstrated that screening with CA-125 and TVUS did not reduce ovarian cancer mortality but significantly increased harms, including unnecessary oophorectomies and surgical complications from false positives. Therefore, routine screening in average-risk women is strongly discouraged.
The PLCO prostate screening arm reported no significant difference in prostate cancer-specific mortality between the screening and control groups. How does the concept of control group contamination complicate the interpretation of these results for a practicing urologist?
Key Response
A major limitation of the PLCO prostate arm was high contamination, with up to 90 percent of the control arm undergoing opportunistic PSA screening during the study period. This blurred the distinction between the groups, potentially masking a true mortality benefit of PSA screening and making it difficult to definitively rule out its utility in specific populations.
How does the cascade of interventions triggered by false-positive results in the PLCO trial, such as biopsies for benign lung nodules or elevated CA-125, reshape our approach to shared decision-making when discussing cancer screening with patients?
Key Response
The PLCO trial powerfully illustrated that screening is not a benign, isolated event but the start of a cascade that can lead to invasive procedures, psychological distress, and physical harm without offering a survival benefit. This mandates that attendings teach trainees to frame screening discussions around the downstream consequences of a positive result, rather than just the initial test.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PLCO trial was designed to evaluate screening for four different cancers within a single large cohort. What are the methodological advantages and statistical challenges, such as alpha inflation and power calculations, of utilizing a multiplex trial design compared to four separate disease-specific RCTs?
Key Response
Methodological advantages include massive cost savings, shared infrastructure, and a unified control group. Challenges include the need for complex power calculations to ensure adequate event rates for each specific cancer, accounting for competing risks of death, and the statistical necessity of adjusting for multiple comparisons to preserve the overall type I error rate without severely compromising power.
When reviewing the baseline demographics of the PLCO cohort, what specific volunteer biases might threaten the external validity of the study, and how would a peer reviewer assess the impact of this on the trial's null findings?
Key Response
PLCO participants were generally healthier, better educated, and more likely to engage in preventive health behaviors than the general population, illustrating the healthy volunteer effect. A critical reviewer would flag that this lower baseline mortality risk and higher background screening rate could bias the results toward the null, as the marginal benefit of an organized screening intervention is diminished in a population already seeking aggressive preventive care.
How did the negative findings of the PLCO trial regarding chest X-ray screening for lung cancer and CA-125/TVUS for ovarian cancer directly shape current USPSTF recommendations, and what subsequent evidence was required to establish the current lung cancer screening paradigm?
Key Response
The PLCO trial definitively ruled out CXR and CA-125/TVUS for screening, reinforcing USPSTF Grade D recommendations against their use in average-risk populations. For lung cancer, guidelines only shifted to a Grade B recommendation for screening after the National Lung Screening Trial (NLST) demonstrated that low-dose CT, unlike CXR, provided a distinct mortality benefit in a high-risk smoking population.
Clinical Landscape
Noteworthy Related Trials
European Randomized Study of Screening for Prostate Cancer (ERSPC)
Tested
PSA-based screening
Population
Men aged 50 to 74 years
Comparator
No screening (usual care)
Endpoint
Prostate-cancer specific mortality
National Lung Screening Trial (NLST)
Tested
Low-dose helical computed tomography (CT)
Population
High-risk current or former heavy smokers aged 55 to 74 years
Comparator
Standard chest X-ray
Endpoint
Lung-cancer specific mortality
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Tested
Multimodal screening (CA125 plus ultrasound) or transvaginal ultrasound alone
Population
Postmenopausal women aged 50 to 74 years
Comparator
No screening
Endpoint
Ovarian-cancer specific mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis